Global News

Forbes names Incyte to list of World’s Most Innovative Companies

Tuesday, August 30, 2016

Incyte has been ranked 4th on Forbes magazine’s 2016 list of the World’s Most Innovative Companies. Incyte, a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, is advancing an innovative and diverse portfolio of large and small molecules comprised of 14 development candidates against 11 different molecular targets.

[Read More]

Biothera Pharmaceuticals, Merck expand cancer immunotherapy collaboration

Tuesday, August 30, 2016

Biothera Pharmaceuticals has announced a collaboration with Merck, known as MSD outside the U.S. and Canada, to expand the companies’ ongoing clinical program evaluating KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 inhibitor, in combination with Biothera’s Imprime PGG, a Pathogen Associated Molecular Patterning molecule, or PAMP. Imprime PGG acts as an immunological “ignition switch” enlisting the innate immune system to enhance the therapeutic efficacy of tumor targeting, anti-angiogenic, and immune checkpoint inhibitor antibodies.

[Read More]

Inovio launches Zika vaccine trial to explore early signals

Monday, August 29, 2016

Inovio Pharmaceuticals has initiated a clinical study of its preventive Zika vaccine (GLS-5700) in 160 subjects in Puerto Rico, where the Zika virus outbreak has been declared a public health emergency. The CDC estimates Zika will infect more than 25% of the Puerto Rican population by year end, providing the potential for this study’s placebo control design to provide exploratory signals of vaccine efficacy.

[Read More]

Metrion Biosciences joins human pain research consortium

Monday, August 29, 2016

Metrion Biosciences, a specialist ion-channel and drug discovery CRO, has entered into an agreement with a network of partners to evaluate the use of primary human dorsal root ganglion (hDRG) neurons in pain research. This Consortium comprises the University of Glasgow, the University of St. Andrews, NHS Greater Glasgow & Clyde (NHS-GGC), Metrion Biosciences, the Grünenthal Group in Germany, and the U.K. National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), with vital support and facilitation by NHS Blood & Transplant (Scotland). 

[Read More]

BioLineRx, I-Bridge Capital establish China joint venture

Friday, August 26, 2016

BioLineRx, a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, has established a joint venture (JV) with I-Bridge Capital, a Chinese venture capital fund focused on developing innovative therapies in China. The joint venture, named iPharma, will develop innovative clinical and preclinical therapeutic candidates originating primarily in Israel to serve the Chinese and global healthcare markets. 

[Read More]

Evofem enrolls first patient in Amphora Gel vaginal Ph trial

Friday, August 26, 2016

Evofem, a biotechnology company focused on the development and commercialization of women’s health products, has announced that patient enrollment has begun in their clinical study that will evaluate the effect and duration of Evofem’s proprietary vaginal gel, Amphora for bacterial vaginosis (BV), on vaginal pH.

[Read More]

Boehringer, Duke collaborate on IPF patient registry

Friday, August 26, 2016

Boehringer Ingelheim Pharmaceuticals and the Duke Clinical Research Institute (DCRI) have announced the expansion of the Idiopathic Pulmonary Fibrosis—PROspective Outcomes (IPF-PRO) Registry, a patient registry developed to uncover insights into IPF, a rare and serious lung disease. The expansion will increase the study enrollment from 300 patients at 18 study sites to 1,500 patients at approximately 45 sites, creating the largest registry of newly diagnosed IPF patients.

[Read More]